 |
5 Diseases |  |
0 Trials |
|
0 Trials |  |
2 News |  |
- | BMS-820132 / BMS
Journal: Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1H-pyrazol-1-yl)methyl)phosphonate (BMS-820132). (Pubmed Central) - May 7, 2022
The synthesis and in vitro and in vivo preclinical pharmacology profiles of 31 and its pharmacokinetics (PK) are described. Based on its promising in vivo efficacy and preclinical ADME and safety profiles, 31 was advanced into human clinical trials.
- ||| BMS-820132 / BMS
Trial completion, Monotherapy: Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes (clinicaltrials.gov) - Feb 27, 2012
P1, N=67, Completed, Sponsor: Bristol-Myers Squibb
Based on its promising in vivo efficacy and preclinical ADME and safety profiles, 31 was advanced into human clinical trials. Recruiting --> Completed